Acquired hypofibrinogenemia in a patient with multiple myeloma

被引:0
作者
Shojiro Inano
Yuki Oku
Akiko Aiba
Naoto Kawasaki
Yoshio Okamoto
Naoki Yuhi
Sho Shibata
Yoko Takiuchi
Sumie Tabata
Toshiyuki Kitano
机构
[1] Kitano Hospital,Department of Hematology
[2] Japanese Red Cross Osaka Hospital,Department of Hematology
来源
International Journal of Hematology | 2021年 / 114卷
关键词
Multiple myeloma; Coagulopathy; Fibrinogen;
D O I
暂无
中图分类号
学科分类号
摘要
We report a case of acquired hypofibrinogenemia with multiple myeloma presenting λ-type IgG monoclonal protein. The patient had anemia and renal deficiency, and also developed bleeding tendency due to severe coagulopathy. Her fibrinogen level was under the detectable limits in a functional assay. Enzyme-linked immunosorbent assay (ELISA) and immunoblotting analysis results were consistent with functional assay results, and deficiency patterns observed in cross-mixing tests for PT and aPTT confirmed the diagnosis of hypofibrinogenemia. To determine the cause of hypofibrinogenemia, we purified the patient’s immunoglobulin via protein A agarose, and confirmed that fibrinogen was included in the bound fraction, strongly indicating paraprotein interference with fibrinogen. As accelerated removal of fibrinogen was indicated, we incubated the patient’s plasma up to 48 h, but did not observe significant loss of fibrinogen. In sharp contrast, fibrinogen returned to below the detection level 12 h after infusion of fresh frozen plasma. These findings support leukocyte-mediated fibrinogen removal, rather than paraprotein-triggered fibrinogen instability. Surprisingly, the patient’s paraprotein was IgG2, but we speculate the amount of paraprotein (IgG 5346 mg/dL) compensated for lower affinity to Fcγ receptors.
引用
收藏
页码:395 / 400
页数:5
相关论文
共 62 条
  • [1] Bagratuni T(2013)Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens Am J Hematol 88 765-770
  • [2] Kastritis E(2005)Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma Blood 106 3777-3784
  • [3] Politou M(2001)Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management Best Pract Res Clin Haematol 14 401-436
  • [4] Roussou M(2013)A case of acquired dysfibrinogenemia in multiple myeloma treated with therapeutic plasma exchange Transfus Apher Sci 48 35-38
  • [5] Kostouros E(2009)Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias Br J Haematol 145 151-163
  • [6] Gavriatopoulou M(2007)Acquired dysfibrinogenemia caused by monoclonal production of immunoglobulin λ light chain Haematologica 92 e111-e117
  • [7] Lonial S(1989)Inhibition of fibrin monomer polymerization by Bence Jones protein in a patient with primary amyloidosis Acta Haematol-Basel 81 160-165
  • [8] Waller EK(2020)Acquired dysfibrinogenemia: monoclonal λ-type IgA binding to fibrinogen caused lower functional plasma fibrinogen level and abnormal clot formation Int J Hematol 112 96-104
  • [9] Richardson PG(2008)Acquired dysfibrinogenemia secondary to multiple myeloma Acta Haematol-Basel 120 75-81
  • [10] Jagannath S(2002)Structure and function of human fibrinogen inferred from dysfibrinogens Int J Hematol 76 352-360